Clinical Trial Update: A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 safety, PK and efficacy study of CC-92480 as monotherapy and in combination with dexamethasone in relapsed and refractory multiple myeloma was termi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CC-92480

Snippet

Sponsor: Celgene | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: TERMINATED